Aurobindo Pharma is currently trading at Rs 1205.00, up by 12.10 points or 1.01% from its previous closing of Rs 1192.90 on the BSE.
The scrip opened at Rs 1212.55 and has touched a high and low of Rs 1212.55 and Rs 1192.80 respectively. So far 8974 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1364.95 on 02-Jan-2025 and a 52-week low of Rs 994.35 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs 1223.10 and Rs 1170.70 respectively. The current market cap of the company is Rs 69742.66 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.81% and 6.38% respectively.
Aurobindo Pharma’s wholly owned subsidiary -- Auro Pharma has approved the acquisition of non-oncology prescription formulations business (the Business) of Khandelwal Laboratories on a going concern basis through a Business Transfer Agreement (BTA). The acquisition of the aforesaid Business shall add further brands in pain management and anti-infective which shall complement the existing product portfolios of the company and help in expanding its business in domestic market. The Business has around 470 people strong field force and has more than 1600 stockists and other distribution related infrastructure.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
